Search hospitals > Florida > Tallahassee

Tallahassee Memorial Hospital

Claim this profile
Tallahassee, Florida 32308
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Coronary Artery Disease
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Coronavirus
109 reported clinical trials
6 medical researchers
Photo of Tallahassee Memorial Hospital in TallahasseePhoto of Tallahassee Memorial Hospital in TallahasseePhoto of Tallahassee Memorial Hospital in Tallahassee

Summary

Tallahassee Memorial Hospital is a medical facility located in Tallahassee, Florida. This center is recognized for care of Lung Cancer, Breast Cancer, Coronary Artery Disease, Non-Small Cell Lung Cancer, Coronavirus and other specialties. Tallahassee Memorial Hospital is involved with conducting 109 clinical trials across 164 conditions. There are 6 research doctors associated with this hospital, such as Thomas Noel, MD, Karen Russell, MD, William Dixon, MD, and Ingrid Jones-Ince, MD.

Area of expertise

1Lung Cancer
Global Leader
Tallahassee Memorial Hospital has run 14 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive
2Breast Cancer
Global Leader
Tallahassee Memorial Hospital has run 12 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage II
Stage I

Top PIs

Clinical Trials running at Tallahassee Memorial Hospital

Breast Cancer
Non-Small Cell Lung Cancer
Pulmonary Embolism
Blood Clot
Cognitive Impairment
Aortic Valve Stenosis
Lung Cancer
Cachexia
Anorexia
Cancer
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Cognitive Training

for Breast Cancer Survivors

This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Recruiting1 award N/A5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Tallahassee Memorial Hospital?
Tallahassee Memorial Hospital is a medical facility located in Tallahassee, Florida. This center is recognized for care of Lung Cancer, Breast Cancer, Coronary Artery Disease, Non-Small Cell Lung Cancer, Coronavirus and other specialties. Tallahassee Memorial Hospital is involved with conducting 109 clinical trials across 164 conditions. There are 6 research doctors associated with this hospital, such as Thomas Noel, MD, Karen Russell, MD, William Dixon, MD, and Ingrid Jones-Ince, MD.